These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30946491)

  • 1. Idarucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemostasis.
    Arellano-Rodrigo E; Fernandez-Gallego V; López-Vilchez I; Molina P; Díaz-Ricart M; Zafar MU; Badimon JJ; van Ryn J; Escolar G
    Transfusion; 2019 Jul; 59(7):2436-2445. PubMed ID: 30946491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers.
    Arellano-Rodrigo E; Lopez-Vilchez I; Galan AM; Molina P; Reverter JC; Carné X; Villalta J; Tassies D; Lozano M; Díaz-Ricart M; Escolar G
    Transfus Med Rev; 2015 Oct; 29(4):242-9. PubMed ID: 26364029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
    Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
    PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
    Honickel M; Maron B; van Ryn J; Braunschweig T; ten Cate H; Spronk HM; Rossaint R; Grottke O
    Thromb Haemost; 2016 Jan; 115(2):271-84. PubMed ID: 26333775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.
    Escolar G; Arellano-Rodrigo E; Lopez-Vilchez I; Molina P; Sanchis J; Reverter JC; Carne X; Cid J; Villalta J; Tassies D; Galan AM; Diaz-Ricart M
    Circ J; 2015; 79(2):331-8. PubMed ID: 25482382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
    Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
    J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation.
    Pujadas-Mestres L; Lopez-Vilchez I; Arellano-Rodrigo E; Reverter JC; Lopez-Farre A; Diaz-Ricart M; Badimon JJ; Escolar G
    PLoS One; 2017; 12(2):e0171486. PubMed ID: 28192448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran.
    Takeshita S; Tanaka KA; Sawa T; Sanda M; Mizobe T; Ogawa S
    Anesth Analg; 2020 Feb; 130(2):535-541. PubMed ID: 31490820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation.
    Božič Mijovski M; Malmström RE; Vene N; Antovic JP; Mavri A
    Sci Rep; 2021 Mar; 11(1):5920. PubMed ID: 33723299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers.
    Schmohl M; Glund S; Harada A; Imazu S; De Smet M; Moschetti V; Ramael S; Ikushima I; Grünenfelder F; Reilly P; Stangier J
    Thromb Haemost; 2017 Jan; 117(2):269-276. PubMed ID: 27904905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
    Grottke O; van Ryn J; Spronk HM; Rossaint R
    Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry.
    Ninivaggi M; Feijge MA; Baaten CC; Kuiper GJ; Marcus MA; Ten Cate H; Lancé MD; Heemskerk JW; van der Meijden PE
    Thromb Haemost; 2014 Mar; 111(3):447-57. PubMed ID: 24258426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
    Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
    Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
    Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma.
    Honickel M; Braunschweig T; Rossaint R; Stoppe C; Ten Cate H; Grottke O
    Anesthesiology; 2017 Nov; 127(5):852-861. PubMed ID: 28857806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin-induced platelet aggregation -effect of dabigatran using automated platelet aggregometry.
    Shimizu M; Natori T; Tsuda K; Yoshida M; Kamada A; Oi K; Ishigaku Y; Oura K; Narumi S; Yamamoto M; Terayama Y
    Platelets; 2020; 31(3):360-364. PubMed ID: 31161848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
    Jacquemin M; Toelen J; Schoeters J; van Horenbeeck I; Vanlinthout I; Debasse M; Peetermans M; Vanassche T; Peerlinck K; van Ryn J; Verhamme P
    J Thromb Haemost; 2015 Nov; 13(11):2087-92. PubMed ID: 26347330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.